Cargando…

Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation

Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanches, Cristina, Alves, Geisa C. S., Farkas, Andras, da Silva, Samuel Dutra, de Castro, Whocely Victor, Chequer, Farah Maria Drummond, Beraldi-Magalhães, Francisco, Magalhães, Igor Rafael dos Santos, Baldoni, André de Oliveira, Chatfield, Mark D., Lipman, Jeffrey, Roberts, Jason A., Parker, Suzanne L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029174/
https://www.ncbi.nlm.nih.gov/pubmed/35453185
http://dx.doi.org/10.3390/antibiotics11040434
_version_ 1784691810628534272
author Sanches, Cristina
Alves, Geisa C. S.
Farkas, Andras
da Silva, Samuel Dutra
de Castro, Whocely Victor
Chequer, Farah Maria Drummond
Beraldi-Magalhães, Francisco
Magalhães, Igor Rafael dos Santos
Baldoni, André de Oliveira
Chatfield, Mark D.
Lipman, Jeffrey
Roberts, Jason A.
Parker, Suzanne L.
author_facet Sanches, Cristina
Alves, Geisa C. S.
Farkas, Andras
da Silva, Samuel Dutra
de Castro, Whocely Victor
Chequer, Farah Maria Drummond
Beraldi-Magalhães, Francisco
Magalhães, Igor Rafael dos Santos
Baldoni, André de Oliveira
Chatfield, Mark D.
Lipman, Jeffrey
Roberts, Jason A.
Parker, Suzanne L.
author_sort Sanches, Cristina
collection PubMed
description Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by HPLC-UV. Population pharmacokinetic modelling was conducted using Pmetrics. Empiric dose of 4 g IV 6- and 8-hourly were simulated for 50 and 100% fT > MIC and the probabil-ity of target attainment (PTA) and the fractional target attainment (FTA) determined. Results: A two-compartment model was designed to describe the pharmacokinetics of critically ill Brazillian patients. Clearance and volume of distribution were (mean ± SD) 3.33 ± 1.24 L h(−1) and 10.69 ± 4.50 L, respectively. Creatinine clearance was positively correlated with piperacillin clearance and a high creatinine clearance was associated with lower values of PTA and FTA. An external vali-dation was performed using data from two different ethnic ICU populations (n = 30), resulting in acceptable bias and precision. Conclusion: The primary pharmacokinetic parameters obtained from critically ill Brazilian patients were similar to those observed in studies performed in critically ill patients of other ethnicities. Based on our results, the use of dose adjustment based on creati-nine clearance is required in Brazilian patients.
format Online
Article
Text
id pubmed-9029174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90291742022-04-23 Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation Sanches, Cristina Alves, Geisa C. S. Farkas, Andras da Silva, Samuel Dutra de Castro, Whocely Victor Chequer, Farah Maria Drummond Beraldi-Magalhães, Francisco Magalhães, Igor Rafael dos Santos Baldoni, André de Oliveira Chatfield, Mark D. Lipman, Jeffrey Roberts, Jason A. Parker, Suzanne L. Antibiotics (Basel) Article Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by HPLC-UV. Population pharmacokinetic modelling was conducted using Pmetrics. Empiric dose of 4 g IV 6- and 8-hourly were simulated for 50 and 100% fT > MIC and the probabil-ity of target attainment (PTA) and the fractional target attainment (FTA) determined. Results: A two-compartment model was designed to describe the pharmacokinetics of critically ill Brazillian patients. Clearance and volume of distribution were (mean ± SD) 3.33 ± 1.24 L h(−1) and 10.69 ± 4.50 L, respectively. Creatinine clearance was positively correlated with piperacillin clearance and a high creatinine clearance was associated with lower values of PTA and FTA. An external vali-dation was performed using data from two different ethnic ICU populations (n = 30), resulting in acceptable bias and precision. Conclusion: The primary pharmacokinetic parameters obtained from critically ill Brazilian patients were similar to those observed in studies performed in critically ill patients of other ethnicities. Based on our results, the use of dose adjustment based on creati-nine clearance is required in Brazilian patients. MDPI 2022-03-24 /pmc/articles/PMC9029174/ /pubmed/35453185 http://dx.doi.org/10.3390/antibiotics11040434 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sanches, Cristina
Alves, Geisa C. S.
Farkas, Andras
da Silva, Samuel Dutra
de Castro, Whocely Victor
Chequer, Farah Maria Drummond
Beraldi-Magalhães, Francisco
Magalhães, Igor Rafael dos Santos
Baldoni, André de Oliveira
Chatfield, Mark D.
Lipman, Jeffrey
Roberts, Jason A.
Parker, Suzanne L.
Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
title Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
title_full Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
title_fullStr Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
title_full_unstemmed Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
title_short Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
title_sort population pharmacokinetic model of piperacillin in critically ill patients and describing interethnic variation using external validation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029174/
https://www.ncbi.nlm.nih.gov/pubmed/35453185
http://dx.doi.org/10.3390/antibiotics11040434
work_keys_str_mv AT sanchescristina populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT alvesgeisacs populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT farkasandras populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT dasilvasamueldutra populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT decastrowhocelyvictor populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT chequerfarahmariadrummond populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT beraldimagalhaesfrancisco populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT magalhaesigorrafaeldossantos populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT baldoniandredeoliveira populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT chatfieldmarkd populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT lipmanjeffrey populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT robertsjasona populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation
AT parkersuzannel populationpharmacokineticmodelofpiperacillinincriticallyillpatientsanddescribinginterethnicvariationusingexternalvalidation